1 **Risk models based on non-cognitive measures may identify presymptomatic**
2 **Alzheimer's disease**
3

4 **Author(s):**
5 Jingjing Yang, PhD[1]; Shahram Oveisgharan, MD[2]; Xizhu Liu[3]; Robert S Wilson, PhD[2]; David A
6 Bennett, MD[2]; Aron S Buchman, MD[2]
7

8 **Corresponding Author:**
9 Jingjing Yang, jingjing.yang@emory.edu
10

11 **Affiliation Information for All Authors**: 1. Center for Computational and Quantitative
12 Genetics, Department of Human Genetics, Emory University School of Medicine, 615 Michael
13 St, Atlanta, GA, 30322, USA; 2. Rush Alzheimer's Disease Center, Rush University Medicine
14 Center, Chicago, IL, 60612, USA; 3. Quantitative Theory and
15 Methods program, College of Arts and Sciences, Emory University, Atlanta, GA, 30322, USA
16

Contributions:
Jingjing Yang: Drafting/revision of the manuscript for content, including medical writing for
content; Study concept
or design; Analysis or interpretation of data
Shahram Oveisgharan: Drafting/revision of the manuscript for content, including medical
writing for content; Major
role in the acquisition of data; Analysis or interpretation of data
Xizhu Liu: Analysis or interpretation of data
Robert S Wilson: Major role in the acquisition of data
David A Bennett: Drafting/revision of the manuscript for content, including medical writing for
content; Major role
in the acquisition of data; Study concept or design; Analysis or interpretation of data
Aron S Buchman: Drafting/revision of the manuscript for content, including medical writing for
content; Major role
in the acquisition of data; Study concept or design; Analysis or interpretation of data
32

Number of Characters in title: 91

Abstract word count: 295

Word count of main text: 4398

References: 50

Figures: 2

Tables: 2

Supplemental: One supplementary data file with 4 supplement figures and 7 supplement
tables are provided

Search Terms: [26] Alzheimer's disease, [36] Cognitive aging, [39] MCI (mild cognitive impairment), [54] Cohort studies

Acknowledgments

We are deeply indebted to all participants who contributed their data and agreed to autopsy at the time of their death. We are thankful to the staff at the Rush Alzheimer's Disease Center.

Study Funding: This work was supported by the National Institute of Health R35GM138313, P30AG10161, K01AG054700, R01AG15819, R01AG17917, R01AG56352; the Illinois Department of Public Health; and the Robert C. Borwell Endowment Fund. The funding organizations had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.

Disclosures: There is no disclosure for all authors.

ABSTRACT

Objective: Examine if non-cognitive metrics alone can be used to construct risk models to
identify adults at risk for Alzheimer's dementia and cognitive impairment, thus enabling early
interventions.

Methods: Clinical data from older adults without dementia from two harmonized cohort
studies, the Memory and Aging Project (MAP, n=1179) and Religious Orders Study (ROS,
n=1103), were analyzed using Cox proportional hazard models with backward variable
selection to develop risk prediction models for Alzheimer's dementia and cognitive impairment.
Models using only non-cognitive covariates of physical function, psychosocial, health
conditions and medications were compared to models that added cognitive covariates of Mini-
Mental Status Examination (MMSE) and composite cognition score summarizing 17 cognitive
tests. All models were trained in MAP and tested in ROS. Model performance was evaluated
by the area under the curves (AUC) of receiver operating characteristic (ROC) curve.

Results: Models based on non-cognitive covariates alone achieved AUC (0.800, 0.785) for
predicting Alzheimer's dementia (3, 5) years from baseline. Including additional cognitive
covariates improved AUC to (0.916, 0.881). A model with a single covariate of composite
cognition score achieved AUC (0.905, 0.863)**.** Models based on non-cognitive covariates alone
achieved AUC (0.717, 0.714) for predicting cognitive impairment (3, 5) years from baseline.
Including additional cognitive covariates improved AUC to (0.783, 0.770). A model with a
single covariate of composite cognition score achieved AUC (0.754, 0.730).

Conclusions: Risk models based on non-cognitive metrics predict both Alzheimer's dementia
and cognitive impairment. However, non-cognitive covariates do not provide incremental
predictivity for models that include cognitive metrics in predicting Alzheimer's dementia, but do
in models predicting cognitive impairment. Risk models of Alzheimer's dementia show more
accurate predictions than the models of cognitive impairment. To ensure early interventions, it
will be necessary to derive improved risk prediction models in particular for cognitive
impairment.

INTRODUCTION

Alzheimer's disease is a progressive disorder that develops over years. An asymptomatic stage during which Alzheimer's disease pathology (AD) accumulates is followed by mild cognitive impairment (MCI), while dementia occurs later.[1-3] Alzheimer's disease is heterogeneous; most demented individuals transition through all three clinical stages i.e., from no cognitive impairment (NCI) to MCI followed by dementia. Some individual's transition directly from NCI to dementia. On the other hand, some never progress beyond MCI and 1/3 with NCI prior to death also show pathologic AD at death.

Early detection of adults with normal cognition at risk for Alzheimer's disease cognitive traits is crucial for early targeted treatments.[4; 5] This underscores the widespread efforts to develop risk prediction models for detecting presymptomatic Alzheimer's disease. Yet, using cognitive test scores as a predictor for the incident cognitive impairment (MCI or Alzheimer's dementia) may be statistically problematic as the same test scores may be used as model predictors as well as for the diagnostic characterization of cognitive status, which is the outcome the model seeks to identify. Moreover, comprehensive cognitive testing requires in-person testing that is not widely available. This highlights the potential benefits of identifying non-cognitive covariates that may be obtained remotely and contain predictive information to identify cognitively normal adults at risk for incident cognitive impairment and Alzheimer's dementia.

Alzheimer's disease is a complex disorder that not only negatively affects cognition, but also adversely affects other important non-cognitive aging phenotypes.[6] For example, accumulation of AD is associated with body mass index (BMI) decline or impaired motor function that may precede and predict incident cognitive impairment and Alzheimer's dementia.[7-10] These data suggest that developing a risk profile based on non-cognitive covariates may facilitate the identification of at risk adults during the earliest stages of Alzheimer's disease.

To test this hypothesis, it is crucial to examine non-cognitive and cognitive covariates alone and together to compare model performance and identify the optimal covariates for predicting incident Alzheimer's dementia and incident cognitive impairment. This study used clinical data from older adults without dementia participating in one of two prospective community-based cohort studies of aging, Rush Memory and Aging Project (MAP) and the Religious Orders Study (ROS).[11] We trained models in MAP and validated model prediction performance in ROS.

METHODS

Participants

Participants were community dwelling older persons enrolled in one of two ongoing cohort studies of aging and dementia, MAP (n=1179) and ROS (n=1103). Participants were enrolled without known dementia; 1742 with NCI and 540 with MCI at enrollment (**Tables S1-S2**). All agreed to annual clinical evaluations and autopsy at the time of death. The duration of follow up for participants ranged from 2 to 26 years, with a median of 8-year and standard deviation 5.42 (**Fig S1**). Both cohorts employ a harmonized data collection battery administered by the same research assistants facilitating joint analyses.

Cognitive Assessment and Diagnoses

Detailed structured clinical examinations were administered annually to participants in both studies. The neuropsychological battery includes 17 tests that assess five domains of cognitive ability. Raw test scores were standardized per test using baseline means and standard deviations (SDs) of both cohorts; the resulting Z-scores were then averaged across the 17 cognitive tests to derive a summary composite cognition score and scores for five cognitive abilities including: episodic memory, semantic memory, working memory, visuospatial abilities, and perceptual speed.

A neuropsychologist and a neurologist with expertise in dementia reviewed annual cognitive testing and classified cognitive status of participants as NCI, MCI, Alzheimer's dementia, or other dementias according to established NIA-AA criteria[11-14]. This study first examined models which predicted transition from no dementia (NCI or MCI) to Alzheimer's dementia (**Fig 1, Row 1**). Second, we examined models which predicted transition from NCI to Alzheimer's dementia (**Fig 1, Row 2**). Third, we studied the outcome of incident cognitive impairment which was defined by the first annual assessment when an individual who was previously cognitively normal (NCI) transitioned to cognitive impairment manifested as either MCI or Alzheimer's dementia (**Fig 1, Row 3**).

Other Clinical Covariates

Five groups of clinical variables (a total of 57) were considered potential covariates in the Cox proportional hazard regression models for risk prediction (**Table 1; Tables S3-S4**) — i) *Common Alzheimer's disease risk factors* including age, sex, education, Mini Mental State Exam (MMSE) score[15] and *APOE* E4 allele; ii) *Health measures* such as blood pressure, depression, and cardiovascular diseases; iii) *Medication usage* such as lipid lowering medications, and antidepressants; iv) *Variables uniquely profiled by MAP/ROS* such as composite cognition scores based on 17 cognitive tests, self-reported physical activity and social network size[11]; v) *Motor and sleep metrics* such as dexterity, hand strength, gait function, four parkinsonian signs[14], and four self-reported variables about sleep quality and duration[13].

These 57 clinical covariates were selected by excluding variables with a high proportion of missing values (>20%) and those that were highly correlated with other clinical variables (correlation>0.95). Missing baseline values of longitudinal variables were imputed from the corresponding values at participant's nearest past visit. A total of 345 individuals with missing cross-sectional variables were excluded, leaving n=1179 MAP and n=1103 ROS participants for these analyses. A heat map showing the correlations of the covariates examined in these models is shown in **Fig S2**.

Analytic Approach

The annual cognitive status diagnosis and the follow up year were used to identify the first occurrence of Alzheimer's dementia or incident cognitive impairment. For each participant, the year of enrollment is considered as baseline (time 0), the year of first diagnosis of Alzheimer's dementia and cognitive impairment (MCI or Alzheimer's dementia) is considered as the time when the event occurs (incident Alzheimer's dementia or incident cognitive impairment), and

the last visit of participants without the considered event during all follow-ups is considered as
the right censored time for living participants or the time of death for dead participants. Less
than 10% of participants developing Alzheimer's dementia progressed directly from NCI to
Alzheimer's dementia. Sample size distributions with respect to cognitive status at baseline
and the cognition event types are included in **Tables S1-S2**.

We fit separate Cox proportional hazard risk prediction models[16-19] for incident Alzheimer's
dementia or incident cognitive impairment while accounting for the competing risk of death. In
the first stage of our analysis, we examined the prediction accuracy of using non-cognitive
covariates alone in the Cox models (Model A). Then, we examined if adding cognitive
covariates improved the model accuracy assessed. Model performance, i.e., discrimination
was evaluated by the prediction area under curve (AUC) values of receiver operating
characteristic curve (ROC)[20] for the risk of developing Alzheimer's dementia and cognitive
impairment 3, 5 years from the analytic baseline. AUC is equal to the probability that a
classifier will rank a randomly chosen individual with the outcome of interest (event or case)
higher than a randomly chosen individual without impaired cognition (control), assuming 'case'
ranks higher than 'control'[20]. That is, the derived risk prediction model with higher AUC is
expected to predict the risk of developing Alzheimer's dementia or cognition impairment with
higher accuracy.

Next, we added the MMSE score (Model B) and then repeated the model a third time adding
the composite cognition score (Model C). In further analyses, we sought to isolate the
prediction accuracy of different combinations of cognitive metrics alone including: composite
cognition score (Model D), MMSE score (Model E), as well as the five cognitive ability scores
(Model F) used for its construction and the 17 individual cognitive test scores (Model G). Since
all covariates were standardized, the magnitudes of covariate coefficients in the Cox models
are comparable with respect to predictivity.

By selecting a risk score threshold corresponding the highest overall classification accuracy
(the proportion of correct discriminations in test ROS samples), we compared the overall
classification, sensitivity (the proportion of true positive predictions in all test cases, i.e., true
positive fraction), and specificity (the proportion of true negative predictions in all test controls,
i.e., 1 – false positive fraction), for Models A-D. Samples with risk scores greater than the
selected threshold were predicted as positives or otherwise negatives. The sensitivity and
specificity corresponding to a selected risk score threshold reflect risk model performance at
one point in the ROC curves.

Backward variable selection was implemented during the training of Cox models that consider
more than one covariate. In particular, we started with the full Cox model with all potential
covariates; proceeded with a temporary Cox model by excluding the covariate with the least
significant p-value; compared their C-statistics (equivalent to AUC) and conducted ANOVA test
to examine if the temporary Cox model would be improved over the current Cox model;
accepted the temporary Cox model if the C-statistic was improved in the temporary Cox model
or otherwise the ANOVA test p-value<0.05. We continued to exclude the covariate with the
least significant p-value from the accepted Cox model until the proposed temporary Cox model
was not accepted or when there was only one covariate remained in the model.

For Alzheimer's dementia, we first considered all individuals including adults with either NCI or
MCI at baseline, and then only individuals with NCI at baseline. Modeling incident cognitive
impairment considered only individuals with NCI at baseline.

All Cox models were trained using data from MAP participants and validated (i.e., tested) with
data from ROS participants[21]. We tested the respective AUC improvement in 3, 5 years of two
models by a nonparametric test that accounts for the correlated nature of the ROC curves[22].
We also evaluated the prediction accuracy, sensitivity, and specificity by choosing the
prediction risk score threshold with respect to the highest overall accuracy.

Standard Protocol Approvals, Registrations, and Patient Consents
Both MAP and ROS studies were approved by an Institutional Review Board of Rush
University Medical Center. Written informed consent was obtained from all study participants
as was an Anatomical Gift Act for organ donation.
230

Data Availability

All data analyzed in this study are de-identified and available to any qualified investigator with
application through the Rush Alzheimer's Disease Center Research Resource Sharing Hub,
https://www.radc.rush.edu, which has descriptions of the studies and available data.

RESULTS

Risk Models Predicting Alzheimer's Dementia

Overall model performance: Cox proportional hazard model trained using only non-cognitive
covariates showed good model performance[23] for predicting Alzheimer's dementia 3, 5 years
from baseline (**Fig 1, Row 1 Model A**). Stepwise addition of the cognitive covariate MMSE and
then composite cognition yielded further significant improvement in the initial model
performance of using only non-cognitive covariates (**Fig 1, Row 1 Model B & Model C**). The
performance accuracy of the full model including non-cognitive covariates, MMSE and
composite cognition score was similar to the performance of a model including composite
cognition score alone (Model D) for Year 3. The full model outperformed Model D for Year 5
(**Fig 1, Row 1 Model C & Model D**).

Important clinical predictors: As expected, composite cognition score had the largest protective
effect size when it was considered in the full model (**Fig 2, Row 1 Model C**). Similarly, in the
model including non-cognitive and MMSE covariates (**Table S5**), we observed that MMSE had
the largest protective effect size, followed by hand strength and *APOE* E2. In contrast,
increasing age and the presence of *APOE* E4 had the largest effect size for increased risk of
Alzheimer's dementia, when only non-cogitive covariates were considered in Model A.

Cognitive metrics as predictors: To better understand the role of cognitive measures in
predicting Alzheimer's dementia, we compared the model performance of different
combinations of cognitive metrics alone for predicting Alzheimer's dementia (**Fig S3 Row 1**).
Model performance for MMSE predicting Alzheimer's dementia (**Fig S3, Row 1 Model E**) was
comparable with a model based only on non-cognitive measures (**Fig 1, Row 1 Model A**). The
various cognitive metrics based on 17 cognitive tests alone (**Fig S3, Row 1 Model F and
Model G**) showed similar excellent model performance that was not improved by the addition

of the non-cognitive covariates or MMSE. Of all the cognitive indices, episodic memory had the
largest protective effect size (**Fig S4, Row 1**).

Exclude baseline MCI patients: Analyses of individuals without dementia include adults with
NCI or MCI at baseline. In further analyses, we restricted our analyses only to individuals with
baseline NCI to see if the same trends were observed despite the truncated heterogeneity of
cognitive function by exclusion of individuals with baseline MCI. Model performance for non-
cognitive covariates for adults with baseline NCI alone was similar to models that also included
adults with baseline MCI (**Fig 1, Row 2 Model A versus Row 1 Model A**). There was
improved model performance when cognitive covariates MMSE or composite cognition scores
were added to the non-cognitive covariates (**Fig 1, Row 2 Model B and Model C**). Yet,
improvement in model performance for predicting dementia in adults with baseline NCI alone
was less marked compared to models that consider adults with baseline NCI or MCI (**Fig 1,**
Row 2 vs. Row 1, Model B and Model C).

Classification accuracy: By comparing the prediction accuracy, sensitivity, and specificity
corresponding to a selected risk score threshold ensures the highest overall accuracy per
model for Models A-D. The pattern in **Table 2** was similar to **Fig 1, Row 1 and Row 2**. That is,
the full Model C performed the best with overall accuracy for Year (3, 5), that outperformed
Model A and Model B for Year (3, 5) when composite cognition was not considered, and
outperformed Model D for Year 5 when only composite cognition was considered. The full
Model C performed comparably with Model D for Year 3.

Risk Models Predicting Cognitive Impairment
Overall model performance: Cox proportional hazard model trained using only non-cognitive
covariates showed adequate model performance[23] for predicting cognitive impairment 3 and 5
years from baseline (**Fig 1, Row 3 Model A**). Yet, discrimination for predicting cognitive
impairment was lower than the model predictions of Alzheimer's dementia (**Fig 1, Row 3 vs.**
Row 1 Model A). Stepwise addition of MMSE and then composite cognition yielded further
improvement in the initial model performance (**Fig 1, Row 3 Model B and Model C**)**.** AUC for
all models predicting cognitive impairment were lower than models predicting Alzheimer's
dementia (**Fig 1 and Fig S3**). The performance accuracy of the full model that included non-
cognitive, MMSE and composite cognition score showed better model performance compared
to models with the composite cognition alone (**Fig 1, Row 3 Model C vs. Model D**).
296
Important clinical predictors: By examining the effect sizes in the Cox model using non-
cognitive and MMSE covariates (**Fig2; Table S5**), we observed that MMSE had the largest
protective effect size and age had the largest effect size for increased risk of cognitive
impairment. Composite cognition still had the largest protective effect for reducing the risk of
cognitive impairment when it was considered in the full model. We observed that age and
APOE E4 were associated with an increased risk of both Alzheimer's dementia and cognitive
impairment. Better motor function was associated with reduced risk of Alzheimer' dementia
(hand strength and gait) and cognitive impairment (hand strength and parkinsonism) (**Fig 2;**
Table S5).

Cognitive function metrics: Next, we compared model performance for several cognitive
metrics alone for predicting cognitive impairment. Model performance for MMSE alone (**Fig S3,**
Row3 Model E) was poor and significantly lower than a model based on all the non-cognitive
covariates together (**Fig 1, Row 3 Model A**). Models using scores of five cognitive abilities
(**Fig S3, Row3 Model F**) or using the 17 individual cognitive test scores (**Fig S3, Row3 Model**
G) had comparable prediction AUC as the model using composite cognition alone (**Fig S3,**
Row3 Model D). These results together with the joint modeling of cognitive and non-cognitive
covariates (**Fig1, Row 3**) show that non-cognitive clinical covariates contain additional
predictive information for predicting cognitive impairment not be accounted for by using
cognitive covariates alone.

Classification accuracy: By comparing the prediction accuracy, sensitivity, and specificity
corresponding to a selected risk score threshold ensures the highest overall accuracy per
model for Models A-D (**Table 2**). These models show a similar pattern to **Fig 1, Row 3**. That
is, the full Model C performed the best with the highest overall accuracy and specificity for
Year (3, 5) performing better than models that did not include global cognition score (A and B)
or a model with global cognition score alone (Model D). So, joint models of non-cognitive and
cognitive measures provide better predictions of cognitive impairment than cognitive measures
alone.

DISCUSSION

Risk models for incident Alzheimer's dementia

This study used a wide range of non-cognitive covariates to construct multifactorial risk models
that as hypothesized yielded good model performance for predicting incident Alzheimer's
dementia. An important aspect of this study was that we examined model performance
achieved by non-cognitive covariates and cognitive function metrics alone and jointly in adults
with no dementia. This analytic approach allows us to isolate the potential improvement in
model performance due to non-cognitive or cognitive covariates. Our results highlight the
effectiveness of cognitive measures alone in predicting Alzheimer's dementia.

While risk models like the Framingham Risk Score have been developed to predict vascular
events[24], there is no widely accepted risk model for the prediction of Alzheimer's dementia or
cognitive impairment[5; 25-30] (**Table S6**). In addition, the aging field has not converged on a
parsimonious set of dementia risk factors that must be included when developing risk models
for cognitive outcomes. Thus, many studies have included cognitive metrics together with non-
cognitive covariates[31; 32] and many other studies have not included cognitive measures[5; 25; 26;
28; 33]. Given the varied covariates employed in prior publications, it is not surprising that model
discrimination has ranged from an AUC of 0.55 to 0.95 for predicting Alzheimer's dementia.
However, even studies reporting models with adequate discrimination have not usually
replicated these findings in independent cohorts. Moreover, there has not been a systematic
effort to clarify the independent roles of non-cognitive versus cognitive metrics for predicting
Alzheimer's dementia as well as consensus about whether to include cognitive measures as
both predictors and outcome in the same models. Nonetheless, review of these past studies

suggests that overall, model performance for predicting Alzheimer's dementia in very old
adults was lower when risk models were based on non-cognitive metrics alone[26].

Our results, validated in an independent cohort, suggest that risk models using non-cognitive
covariates show good model performance and predict Alzheimer's dementia. We also showed
that this good performance was further improved by adding cognitive scores. Yet, further
analyses showed that the risk models based on composite cognitive metrics alone achieved
better model performance than the model based on non-cognitive covariates and MMSE for
Alzheimer's dementia (**Fig 1, Row 1**). By restricting our modeling only to adults with NCI, we
showed that non-cognitive variables add additional predictive information that cannot be
accounted for by the composite cognitive scores alone for predicting Alzheimer's dementia
(**Fig 1, Row 2**). These results may have important clinical consequences for public health
efforts to identify adults with presymptomatic Alzheimer's disease, i.e., NCI at risk for future
dementia. Further work is needed to identify non-cognitive covariates or AD biomarkers that
may improve risk models in adults with NCI at the earliest stages of Alzheimer's disease

Risk models for incident cognitive impairment

Transition from NCI to MCI, an earlier stage in the trajectory of Alzheimer's disease, occurred
in almost all participants (>90%) who developed Alzheimer's dementia in MAP/ROS studies.
Since the biology underlying earlier and later stages of Alzheimer's disease may vary, their
respective risk models may be different.[3] Compared to studying Alzheimer's dementia, larger
sample size and wider range of clinical variables are needed for studying cognitive impairment
that includes transition from NCI to either MCI or Alzheimer's dementia. Thus, there are far
fewer studies which have developed risk models for predicting cognitive impairment as
compared to dementia and even fewer have validated findings in independent samples. Model
performances reported for predicting cognitive impairment have varied widely (**Table S7**).[32; 34-
36] We are unaware of studies that isolated the independent and joint contributions of non-
cognitive and cognitive metrics for model discrimination of incident cognitive impairment.

Our study found that risk models for cognitive impairment based on only non-cognitive
covariates showed adequate model performance but consistently poorer than prediction
models for Alzheimer's dementia (**Fig 1 Row 2 vs Row 3**). While adding cognitive covariates
in addition to non-cognitive covariates improved model performance predicting cognitive
impairment, overall performance never equaled model performance for predicting Alzheimer's
dementia. These findings highlight the importance of further studies to identify additional
clinical metrics or biomarkers to improve the prediction of cognitive impairment.

Risk models for cognitive impairment versus Alzheimer's dementia

An additional strength of the current study design is that we compared the performances of
models predicting cognitive impairment and Alzheimer's dementia using the same covariates
and individuals with NCI at baseline. In addition, we validated our results in an independent
sample of older adults. Model performance for predicting Alzheimer's dementia was much
better than models predicting cognitive impairment. These findings may derive from the
differences in the symptoms and diagnoses of MCI versus Alzheimer's dementia. That is,
discriminating symptoms of Alzheimer's dementia from NCI/MCI is generally much easier than
discriminating symptoms of MCI from NCI. There is more random error and instability in the

diagnosis of MCI compared to dementia. Many prior studies have reported lower sensitivity
and specificity for cognitive instruments used to identify MCI compared to Alzheimer's
dementia.[37] Individuals with MCI show more fluctuations between NCI and MCI during
repeated cognitive testing. In contrast, once individuals receive a diagnosis of dementia, they
are less likely to revert back to NCI/MCI on repeated testing.

Yet, varied model performance for predicting cognitive impairment and Alzheimer's dementia
may inform differences in the respective biology underlying these Alzheimer's clinical traits.[38]
Additionally, the associations between a specific risk factor with dementia may vary over time.
For example, high BMI in mid-life may be related to an increased risk of dementia, while high
BMI in much older adults may be related to decreased risk of dementia.[39] Analogously, in
earlier stages of Alzheimer's disease, the burden and location of AD may lead to impaired non-
cognitive function like motor function to a greater extent than cognition. In contrast, during its
later stages the widespread accumulation of AD throughout cognitive brain regions may have a
larger pervasive negative impact on cognition. This might account for better performance
achieved by cognitive metrics for Alzheimer's dementia and the lack of incremental validity of
non-cognitive covariates when considered together with cognitive metrics for Alzheimer's
dementia. This might also account for the incremental predictivity of non-cognitive covariates in
addition to cognitive metrics for incident cognitive impairment.

Implications of the current findings

The reconceptualization of Alzheimer's disease as a chronic progressive disorder that
develops over many years suggests that treatments during its earliest stage when adults
manifest normal cognitive function may offer the best chance of preventing future cognitive
impairment. However, this opportunity requires the identification of at-risk older adults who are
likely to benefit from early interventions. Thus, our findings are timely as they inform on how to
optimize the construction of models to identify at risk older adults.[40] [1,2] To date there is no
consensus about whether cognitive function metrics can or should be included together with
non-cognitive function metrics for predicting Alzheimer's dementia. The current results
demonstrate the importance of addressing this issue since including cognitive function metrics
can impact model performance and the value added for non-cognitive measures used to
construct risk models for different Alzheimer's cognitive phenotypes.

Examining important predictive covariates selected in our Cox risk models highlights the
importance of motor function (e.g., hand strength and Parkinsonian gait score) as one of the
most important non-cognitive covariates in predicting both incident Alzheimer's dementia and
incident cognitive impairment. Although our previous study showed that when cognitive metrics
are considered motor function did not show incremental predictivity for Alzheimer's dementia[41],
this study showed that motor metrics provide additional predictive information for both
Alzheimer's dementia and cognitive impairment (**Fig 2; Table S5**). Motor planning and ongoing
attention is necessary for all movement. Thus, the fact that "we must think first and then move
next" may explain why motor metrics predict cognitive impairment. Yet conventional motor
testing only quantifies movement and does not assess specific cognitive indices underlying
motor planning or executive and attentional resources crucial for movement execution.
Instrumented gait testing with unobtrusive sensors can be used to quantify cognitive mobility
metrics which precede movement.[42,43] Further work is needed to determine if adding additional

cognitive mobility metrics may improve predictions of adults at risk for Alzheimer's dementia
and cognitive impairment.

Also, broadening the motor metrics used to predict cognitive impairment might help circumvent
statistical concerns about confounding predictors with model outcomes as cognitive mobility
metrics are not part of current cognitive batteries used to document dementia or cognitive
impairment. While there are many knowledge gaps in our understanding of the trajectory for
the accumulation of AD pathology, the time course for β-amyloid and tau-tangles during the
early and later stages of Alzheimer's disease may vary; so fluid biomarkers of AD traits might
be particularly helpful for improving model performance [32; 44]. Finally, leveraging the rapid
advances in machine learning suggests that it may be possible to impute and include
underlying AD pathologies to improve model performances.[21; 45-49]

Strength & Limitations

The study has several strengths that lend confidence for the current findings. All subjects were
recruited from the community, underwent an annual detailed clinical evaluation, and were
determined to be free of dementia at study entry. Large numbers of men and women
underwent annual assessments, and follow-up rates were very high. Uniform, structured
procedures were followed that enhanced stability of diagnoses across time, space, and
examiners. Diverse non-cognitive covariates were examined. An important strength of the
current study design is that we compared the performances of models predicting cognitive
impairment and Alzheimer's dementia in the same individuals with identical covariates[50].
Moreover, we were able to replicate our results in an independent sample of older adults who
underwent the same assessments and testing by the same staff. However, further studies will
be needed due to limitations. Participants were predominantly Americans of European descent
and have higher than average levels of education, so our findings will need to be replicated in
more diverse populations. Brain imaging and fluid biomarkers were not examined. The
particular cognitive battery employed is more extensive than what might be available outside of
a research setting highlighting the importance of our findings using the MMSE.

Appendix 1. Authors

Name	Location	Contribution
Jingjing Yang, PhD	Emory University School of Medicine	Design and conceptualized study; analyzed the data; drafted the manuscript for intellectual content
Shahram Oveisgharan, MD	Rush University Medical Center	Major role in the acquisition of data; interpreted the data; revised the manuscript for intellectual content
Xizhu Liu	Emory University College of Arts and Science	Analyzed the data
Robert S. Wilson, PhD	Rush University Medical Center	Major role in the acquisition of data; revised the manuscript for intellectual content
David A. Bennett, MD	Rush University Medical Center	Design and conceptualized study; major role in the acquisition of data; interpreted the data; revised the manuscript for intellectual content
Aron S. Buchman, MD	Rush University Medical Center	Design and conceptualized study; interpreted the data; revised the manuscript for intellectual content

Figure Legends

Fig 1. ROC plots of risk prediction for incident Alzheimer's dementia and incident cognitive impairment with non-cognitive and cognitive covariates alone and together. Model A uses 55 non-cognitive covariates; Model B 55 non-cognitive covariates + MMSE; Model C 55 non-cognitive covariates+ MMSE+ Composite Cognition; Model D uses only Composite Cognition.
ROW 1 No dementia (NCI or MCI) at baseline and incident Alzheimer's Dementia: Model B vs A showed significant improvement with p-values=(4.85×10^{-4}, 1.09×10^{-4}) for Year (3, 5). Model C vs B showed significant improvement with p-values=(7.55×10^{-7}, 9.15×10^{-6}) for Year (3, 5). Model C vs D for Year 3 (p-value = 0.156) but significant improvement for Year 5 (p-value = 0.033).
ROW 2 NCI at baseline and incident Alzheimer's Dementia: Model B vs A showed significant improvement only for Year 3 with p-value=0.042 but not for Year 5 with p-value=0.185. Model C vs A/B showed significant improvement p-values=~(0.004, 0.019) for Year (3, 5). Model C vs D showed comparable performance for Year 3 with p-value=0.156 but significant improvement for Year 5 with p-value=0.025.
ROW 3 NCI and incident cognitive impairment: Model B vs A showed significant improvement p-values p-values=(0.002, 0.008) for Year (3, 5). Model C vs B showed significant improvement p-values=(0.001, 0.001) for Year (3, 5). Model C vs D showed significant improvement p-values=(0.029, 0.002) for Year (3, 5).

Fig 2. Important predictive covariates predicting incident Alzheimer's dementia and incident cognitive impairment.
ROW 1 No dementia (NCI or MCI) at baseline and incident Alzheimer's Dementia: Age and APOE E4 allele were identified as the top positive risk factors in all three models. Hand strength was the top protective factor in Model A when no cognitive covariates were considered. MMSE was the top protective factor in Model B when composite cognition was not considered. Composite cognition score was the top protective factor in Model C where all clinical covariates were considered.
ROW 2 NCI at baseline and incident Alzheimer's Dementia: Age was identified as the top positive risk factor in all three models. Motor gait and hand strength were top protective factor in Model A and Model B when composite cognition score was not considered. Instead of composite cognition score, vascular disease history at baseline was the top "protective" factor in Model C, which might lead to death before the development of Alzheimer's dementia.
ROW 3 NCI and incident cognitive impairment: Age and education were identified as top positive risk factors in all three models, where education years were positively correlated with the number of follow-up years in ROS/MAP. Hand strength and social network size were top protective factor in Model A when no cognitive covariates were considered. MMSE was the top protective factor in Model B when composite cognition was not considered. Composite cognition score was the top protective factor in Model C where all clinical covariates were considered.

508 **Table 1. Select clinical characteristics of the analytic cohort at baseline (n=1179 in MAP;**
509 **n=1103 in ROS).**
510

Group	Variable	Mean (SD) or N (%)
Demographics and Common Alzheimer's Risk Factors	Mild cognitive impairment (N)	541 (23.7)
	Follow-up years (2-26)	8 (5.42)
	Age (years, 53-102)	77.4 (7.51)
	Sex (males, N)	577 (25.2)
	Education (years, 0-30)	16.5 (3.65)
	BMI (9.09, 62.91)	27.52 (5.50)
	MMSE Score (18-30)	28.37 (1.73)
	APOE E2 (carriers, N)	330 (14.4)
	APOE E4 (carriers, N)	513 (22.4)
Covariates Uniquely Profiled by ROS/MAP	Composite cognition test Z-score (-1.95, 1.47)	0.32 (0.51)
	Physical activity (0-35)	3.19 (3.79)
	Social network size (0, 162)	7.58 (7.52)
	Maternal education (years, 0-20)	9.66 (3.79)
	Paternal education (years, 0-24)	9.60 (4.26)
	Anxiety (0-10)	1.28 (1.69)
	Proneness to psychological distress (0-42)	15.69 (6.44)
	Tendency to be social, active, and optimistic (5, 24)	15.52 (3.14)
	Early life socioeconomic status Z-score (-2.72, 2.15)	0.02 (0.74)
	Anger (0-10)	1.76 (1.88)
	TOMM40_S (N)	1,126 (49.2)
	TOMM40_L (N)	371 (16.2)
	TOMM40_VL (N)	1,114 (48.7)
Motor Metrics	Dexterity (0, 1.85)	1.02 (0.16)
	Gait function (0, 2.13)	1.05 (0.27)
	Hand strength (0, 2.36)	1.07 (0.30)
	Bradykinesia (0, 85)	8.82 (10.6)
	Parkinsonian gait (0, 85.18)	12.16 (13.45)
	Rigidity (0, 60)	2.15 (5.88)
	Tremor (0, 69.69)	2.23 (5.02)
Self-reported Sleep Metrics	Sleep latency (1, 9)	3.63 (1.14)
	Sleep consolidation (1, 8)	2.92 (1.31)
	Daytime sleepiness (1, 5)	3.21 (1.33)
	Sleep quality (1, 5)	2.10 (1.05)

511
512
513

Table 2. Prediction accuracy (with 95% confidence interval), sensitivity, and specificity
with respect to selected risk score thresholds that ensure the highest overall accuracy.
Values in this table are reflecting risk model prediction performance at one point in the ROC
curves as shown in Fig1, with corresponding risk score thresholds. Samples with predicted risk
scores greater than the selected threshold were considered as Predicted Positives (incident
Alzheimer's dementia or incident cognitive impairment), otherwise Predicted Negatives (not
developing Alzheimer's dementia or NCI).
521

		Model A. Non-Cognitive Covariates		Model B. MMSE + Non-Cognitive Covariates		Model C. MMSE + Composite Cognition + Non-Cognitive Covariates		Model D. Composite Cognition	
		Y3	Y5	Y3	Y5	Y3	Y5	Y3	Y5
NCI/MCI -> Alzheimer's Dementia	**Accuracy[a] (95% CI)**	0.664 (0.637, 0.694)	0.616 (0.586, 0.644)	0.761 (0.735, 0.786)	0.707 (0.679, 0.734)	0.856 (0.834, 0.876)	0.816 (0.792, 0.838)	0.865 (0.844, 0.885)	0.784 (0.758, 0.808)
	Sensitivity[b]	0.810	0.804	0.810	0.804	0.810	0.804	0.810	0.804
	Specificity[c]	0.655	0.591	0.757	0.694	0.860	0.817	0.870	0.781
NCI -> Alzheimer's Dementia	**Accuracy[a] (95% CI)**	0.688 (0.655, 0.719)	0.701 (0.669, 0.732)	0.790 (0.761, 0.818)	0.695 (0.662, 0.726)	0.818 (0.790, 0.844)	0.763 (0.733, 0.791)	0.806 (0.778, 0.832)	0.645 (0.611, 0.677)
	Sensitivity[b]	0.800	0.804	0.800	0.804	0.800	0.804	0.800	0.804
	Specificity[c]	0.685	0.695	0.790	0.689	0.818	0.761	0.806	0.636
NCI -> Cognitive Impairment	**Accuracy[a] (95% CI)**	0.650 (0.617, 0.682)	0.635 (0.601, 0.667)	0.662 (0.629, 0.693)	0.648 (0.614, 0.680)	0.701 (0.669, 0.732)	0.685 (0.679, 0.716)	0.672 (0.639, 0.703)	0.657 (0.624, 0.689)
	Sensitivity[b]	0.700	0.700	0.700	0.700	0.700	0.700	0.700	0.700
	Specificity[c]	0.635	0.604	0.650	0.623	0.702	0.678	0.664	0.636

522 a. Accuracy= (# True Positive Predictions + # True Negative Predictions) / (# of test samples)
523 b. Sensitivity = (# True Positive Predictions) / (# Positives in test samples) = True Positive Fraction
524 c. Specificity = (# True Negative Predictions) / (# Negatives in test samples) = 1 - False Positive Fraction
525
526

References

1. Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., and Jones, E. (2011). Alzheimer's disease. Lancet 377, 1019-1031.

2. Burns, A., and Iliffe, S. (2009). Alzheimer's disease. BMJ 338, b158.

3. Jack, C.R., Jr., Albert, M., Knopman, D.S., McKhann, G.M., Sperling, R.A., Carrillo, M.C., Thies, B., and Phelps, C.H. (2011). Introduction to revised criteria for the diagnosis of Alzheimer's disease: National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 7, 256-262.

4. Barnes, D.E., and Lee, S.J. (2011). Predicting Alzheimer's risk: why and how? Alzheimer's Research & Therapy 3, 33.

5. Reitz, C., Tang, M.X., Schupf, N., Manly, J.J., Mayeux, R., and Luchsinger, J.A. (2010). A summary risk score for the prediction of Alzheimer disease in elderly persons. Arch Neurol 67, 835-841.

6. Albers, M.W., Gilmore, G.C., Kaye, J., Murphy, C., Wingfield, A., Bennett, D.A., Boxer, A.L., Buchman, A.S., Cruickshanks, K.J., Devanand, D.P., et al. (2015). At the interface of sensory and motor dysfunctions and Alzheimer's disease. Alzheimers Dement 11, 70-98.

7. Buchman, A.S., Schneider, J.A., Wilson, R.S., Bienias, J.L., and Bennett, D.A. (2006). Body mass index in older persons is associated with Alzheimer disease pathology. Neurology 67, 1949-1954.

8. Buchman, A.S., Wilson, R.S., Bienias, J.L., Shah, R.C., Evans, D.A., and Bennett, D.A. (2005). Change in body mass index and risk of incident Alzheimer disease. Neurology 65, 892-897.

9. Yu, L., Boyle, P.A., Leurgans, S.E., Wilson, R.S., Bennett, D.A., and Buchman, A.S. (2019). Incident Mobility Disability, Mild Cognitive Impairment, and Mortality in Community-Dwelling Older Adults. Neuroepidemiology, 1-8.

10. Beeri, M.S., Leugrans, S.E., Delbono, O., Bennett, D.A., and Buchman, A.S. (2021). Sarcopenia is associated with incident Alzheimer's dementia, mild cognitive impairment, and cognitive decline. J Am Geriatr Soc.

11. Bennett, D.A., Buchman, A.S., Boyle, P.A., Barnes, L.L., Wilson, R.S., and Schneider, J.A. (2018). Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis 64, S161-S189.

12. Bennett, D.A., Wilson, R.S., Schneider, J.A., Evans, D.A., Beckett, L.A., Aggarwal, N.T., Barnes, L.L., Fox, J.H., and Bach, J. (2002). Natural history of mild cognitive impairment in older persons. Neurology 59, 198-205.

13. Park, M., Buchman, A.S., Lim, A.S., Leurgans, S.E., and Bennett, D.A. (2014). Sleep complaints and incident disability in a community-based cohort study of older persons. Am J Geriatr Psychiatry 22, 718-726.

14. Buchman, A.S., Yu, L., Oveisgharan, S., Petyuk, V.A., Tasaki, S., Gaiteri, C., Wilson, R.S., Grodstein, F., Schneider, J.A., Klein, H.-U., et al. (2021). Cortical proteins may provide motor resilience in older adults. Scientific Reports 11, 11311.

15. Tombaugh, T.N., and McIntyre, N.J. (1992). The mini-mental state examination: a
comprehensive review. J Am Geriatr Soc 40, 922-935.

16. Cox, D.R. (1972). Regression models and life‑tables. Journal of the Royal Statistical
Society: Series B (Methodological) 34, 187-202.

17. Benichou, J., and Gail, M.H. (1990). Estimates of absolute cause-specific risk in cohort
studies. Biometrics 46, 813-826.

18. Gerds, T.A., Scheike, T.H., and Andersen, P.K. (2012). Absolute risk regression for
competing risks: interpretation, link functions, and prediction. Stat Med 31, 3921-3930.

19. Ozenne, B., Sørensen, A.L., Scheike, T., Torp-Pedersen, C., and Gerds, T.A. (2017).
riskRegression: predicting the risk of an event using Cox regression models. The R
Journal 9, 440-460.

20. Linden, A. (2006). Measuring diagnostic and predictive accuracy in disease management:
an introduction to receiver operating characteristic (ROC) analysis. J Eval Clin Pract 12,
132-139.

21. Hastie, T., Tibshirani, R., and Friedman, J.S. (2009). The Elements of Statistical
Learning.(Springer-Verlag New York).

22. DeLong, E.R., DeLong, D.M., and Clarke-Pearson, D.L. (1988). Comparing the areas
under two or more correlated receiver operating characteristic curves: a nonparametric
approach. Biometrics 44, 837-845.

23. Mandrekar, J.N. (2010). Receiver operating characteristic curve in diagnostic test
assessment. J Thorac Oncol 5, 1315-1316.

24. D'Agostino, R.B., Sr., Vasan, R.S., Pencina, M.J., Wolf, P.A., Cobain, M., Massaro, J.M.,
and Kannel, W.B. (2008). General cardiovascular risk profile for use in primary care: the
Framingham Heart Study. Circulation 117, 743-753.

25. Kivipelto, M., Ngandu, T., Laatikainen, T., Winblad, B., Soininen, H., and Tuomilehto, J.
(2006). Risk score for the prediction of dementia risk in 20 years among middle aged
people: a longitudinal, population-based study. Lancet Neurol 5, 735-741.

26. Walters, K., Hardoon, S., Petersen, I., Iliffe, S., Omar, R.Z., Nazareth, I., and Rait, G.
(2016). Predicting dementia risk in primary care: development and validation of the
Dementia Risk Score using routinely collected data. BMC Med 14, 6.

27. Vos, S.J.B., van Boxtel, M.P.J., Schiepers, O.J.G., Deckers, K., de Vugt, M., Carriere, I.,
Dartigues, J.F., Peres, K., Artero, S., Ritchie, K., et al. (2017). Modifiable Risk Factors
for Prevention of Dementia in Midlife, Late Life and the Oldest-Old: Validation of the
LIBRA Index. J Alzheimers Dis 58, 537-547.

28. Li, J., Ogrodnik, M., Devine, S., Auerbach, S., Wolf, P.A., and Au, R. (2018). Practical risk
score for 5-, 10-, and 20-year prediction of dementia in elderly persons: Framingham
Heart Study. Alzheimers Dement 14, 35-42.

29. Anstey, K.J., Cherbuin, N., Herath, P.M., Qiu, C., Kuller, L.H., Lopez, O.L., Wilson, R.S.,
and Fratiglioni, L. (2014). A self-report risk index to predict occurrence of dementia in
three independent cohorts of older adults: the ANU-ADRI. PloS one 9, e86141.

30. van Middelaar, T., Hoevenaar-Blom, M.P., van Gool, W.A., Moll van Charante, E.P., van
Dalen, J.W., Deckers, K., Kohler, S., and Richard, E. (2018). Modifiable dementia risk
score to study heterogeneity in treatment effect of a dementia prevention trial: a post
hoc analysis in the preDIVA trial using the LIBRA index. Alzheimers Res Ther 10, 62.

31. Belleville, S., Fouquet, C., Hudon, C., Zomahoun, H.T.V., Croteau, J., and Consortium for
the Early Identification of Alzheimer's, d.-Q. (2017). Neuropsychological Measures that
Predict Progression from Mild Cognitive Impairment to Alzheimer's type dementia in
Older Adults: a Systematic Review and Meta-Analysis. Neuropsychol Rev 27, 328-353.

32. Albert, M., Zhu, Y., Moghekar, A., Mori, S., Miller, M.I., Soldan, A., Pettigrew, C., Selnes,
O., Li, S., and Wang, M.C. (2018). Predicting progression from normal cognition to mild
cognitive impairment for individuals at 5 years. Brain 141, 877-887.

33. Lin, H.R., Tsuji, T., Kondo, K., and Imanaka, Y. (2018). Development of a risk score for the
prediction of incident dementia in older adults using a frailty index and health checkup
data: The JAGES longitudinal study. Prev Med 112, 88-96.

34. Pankratz, V.S., Roberts, R.O., Mielke, M.M., Knopman, D.S., Jack, C.R., Jr., Geda, Y.E.,
Rocca, W.A., and Petersen, R.C. (2015). Predicting the risk of mild cognitive impairment
in the Mayo Clinic Study of Aging. Neurology 84, 1433-1442.

35. Steenland, K., Zhao, L., John, S.E., Goldstein, F.C., Levey, A., Alvaro, A., and Alzheimer's
Disease Neuroimaging, I. (2018). A 'Framingham-like' Algorithm for Predicting 4-Year
Risk of Progression to Amnestic Mild Cognitive Impairment or Alzheimer's Disease
Using Multidomain Information. J Alzheimers Dis 63, 1383-1393.

36. Fouladvand, S., Mielke, M.M., Vassilaki, M., Sauver, J.S., Petersen, R.C., and Sohn, S.
(2019). Deep Learning Prediction of Mild Cognitive Impairment using Electronic Health
Records. Proceedings (IEEE Int Conf Bioinformatics Biomed) 2019, 799-806.

37. Patnode, C.D., Perdue, L.A., Rossom, R.C., Rushkin, M.C., Redmond, N., Thomas, R.G.,
and Lin, J.S. (2020). Screening for Cognitive Impairment in Older Adults: Updated
Evidence Report and Systematic Review for the US Preventive Services Task Force.
Jama 323, 764-785.

38. Zammit, A.R., Yu, L., Petyuk, V., Schneider, J.A., De Jaeger, P.L., Klein, H.-U., Bennett ,
D.A., and Buchman, A.S. (2022). Aggregation of cortical resilience proteins yields
person-specific indices of cognitive resilience. Neurology In Press.

39. García-Ptacek, S., Faxén-Irving, G., Cermáková, P., Eriksdotter, M., and Religa, D. (2014).
Body mass index in dementia. Eur J Clin Nutr 68, 1204-1209.

40. Jack, C.R., Bennett, D.A., and Blennow, K. (2018). 2018 NIA-AA research framework to
investigate the Alzheimer's disease continuum.

41. Beeri, M.S., Leurgans, S.E., Bennett, D.A., Barnes, L.L., and Buchman, A.S. (2021).
Diverse Motor Performances Are Related to Incident Cognitive Impairment in
Community-Dwelling Older Adults. Front Aging Neurosci 13, 717139.

42. Gazit, E., Buchman, A.S., Dawe, R., Curran, T.A., Mirelman, A., Giladi, N., and Hausdorff,
J.M. (2020). What happens before the first step? A New Approach to Quantifying Gait
Initiation Using a Wearable Sensor. Gait Posture 76, 128-135.

43. Bayot, M., Dujardin, K., Tard, C., Defebvre, L., Bonnet, C.T., Allart, E., and Delval, A.
(2018). The interaction between cognition and motor control: A theoretical framework for
dual-task interference effects on posture, gait initiation, gait and turning. Neurophysiol
Clin 48, 361-375.

44. Rosenberg, A., Solomon, A., Jelic, V., Hagman, G., Bogdanovic, N., and Kivipelto, M.
(2019). Progression to dementia in memory clinic patients with mild cognitive
impairment and normal beta-amyloid. Alzheimers Res Ther 11, 99.

45. Zou, H., and Hastie, T. (2005). Regularization and variable selection via the elastic net.
Journal of the Royal Statistical Society: Series B (Statistical Methodology) 67, 301-320.

46. Nagpal, S., Meng, X., Epstein, M.P., Tsoi, L.C., Patrick, M., Gibson, G., De Jager, P.L.,
Bennett, D.A., Wingo, A.P., Wingo, T.S., et al. (2019). TIGAR: An Improved Bayesian
Tool for Transcriptomic Data Imputation Enhances Gene Mapping of Complex Traits.
American journal of human genetics 105, 258-266.

47. Luningham, J.M., Chen, J., Tang, S., De Jager, P.L., Bennett, D.A., Buchman, A.S., and
Yang, J. (2020). Bayesian Genome-wide TWAS Method to Leverage both cis- and
trans-eQTL Information through Summary Statistics. American journal of human
genetics 107, 714-726.

48. Tang, S., Buchman, A.S., De Jager, P.L., Bennett, D.A., Epstein, M.P., and Yang, J.
(2021). Novel Variance-Component TWAS method for studying complex human
diseases with applications to Alzheimer's dementia. PLoS genetics 17, e1009482.

49. Wingo, A.P., Liu, Y., Gerasimov, E.S., Gockley, J., Logsdon, B.A., Duong, D.M., Dammer,
E.B., Robins, C., Beach, T.G., Reiman, E.M., et al. (2021). Integrating human brain
proteomes with genome-wide association data implicates new proteins in Alzheimer's
disease pathogenesis. Nat Genet 53, 143-146.

50. Licher, S., Yilmaz, P., Leening, M.J.G., Wolters, F.J., Vernooij, M.W., Stephan, B.C.M.,
Ikram, M.K., and Ikram, M.A. (2018). External validation of four dementia prediction
models for use in the general community-dwelling population: a comparative analysis
from the Rotterdam Study. Eur J Epidemiol 33, 645-655.